Corporate | 10 October 2011 07:56
|
WILEX AG / Key word(s): Agreement
PRESS RELEASE WILEX Inc. and ALPCO Diagnostics sign marketing and distribution agreement for North America Munich, Germany / Salem, NH, USA 10 October 2011. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced that its wholly owned US subsidiary WILEX Inc., Cambridge, MA, USA, entered into a exclusive co-marketing and distribution agreement with American Laboratory Products Company Inc., (ALPCO Diagnostics) Salem, NH, USA, for the commercialization of the Serum HER-2/neu ELISA test in North America (USA and Canada). ALPCO Diagnostics is a leading developer and distributor of high quality immunoassays for use in both life science research as well as esoteric diagnostic testing applications. WILEX' test is the only FDA-cleared IVD ELISA that quantifies the serum HER-2/neu level for the management and monitoring of patient care for women with metastatic breast cancer. Under the terms of the agreement WILEX Inc. retains its own marketing and distribution rights for North America. Financial terms were not disclosed. Prof Olaf G. Wilhelm, CEO of WILEX Inc. and WILEX AG, comments: 'ALPCO has more than 20 years of service and experience in supporting customers in the scientific application of ALPCO's products. This has allowed the company to foster strong and lasting relationships with both the reference laboratories performing the tests, and key opinion leaders applying the information from the results. We therefore believe that ALPCO is an ideal partner to successfully co-distribute the HER-2/neu ELISA test in North America.' Sean Conley, President of ALPCO, said: 'We are pleased with the recent addition to ALPCO's product portfolio as we feel this HER-2/neu ELISA test is currently under-utilized and will offer our routine clinical lab customers and their respective physician clients an important diagnostic application for improving patient care'.
About American Laboratory Products Company (ALPCO Diagnostics)
About WILEX Inc.
About
WILEX AG
Contact
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will' 'should' 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. End of Corporate News 10.10.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | WILEX AG | |
| Grillparzerstr. 10 | ||
| 81675 München | ||
| Germany | ||
| Phone: | +49 (0)89 41 31 38 – 0 | |
| Fax: | +49 (0)89 41 31 38 – 99 | |
| E-mail: | info@wilex.com | |
| Internet: | www.wilex.com | |
| ISIN: | DE0006614720 | |
| WKN: | 661472 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 141724 10.10.2011 |